Zoetis (ZTS) stock is currently trading at a significant discount to the S&P 500 median, with a price-to-earnings multiple of 13.5 compared to 22.3 for the broader index. Over the past twelve months, shares have declined by 29.6%, leading some analysts to question whether the market assumes the company has ceased growth. The article investigates if this valuation gap represents a buying opportunity or reflects genuine fundamental deterioration in Zoetis's business model. Despite the lower valuation, Zoetis maintains robust profitability with an operating margin of 37.7% over the four quarters ended September 2026, significantly outpacing the S&P 500 median of 19.0%. The company also trades at a discount on cash flow, priced at 12.4 times operating cash flow versus 14.9 for the broader market. However, net income and operating cash flow have recently declined, with net income falling to $2.51 billion from $2.63 billion in the prior year. Revenue growth has nearly stalled, expanding by only 0.9% in the latest quarter compared to a 4.3% average over the previous three periods. The primary driver of this slowdown is a decline in dermatology medicines, which lost 16% worldwide in the most recent quarter as key products like Apoquel lost market share to generic competition. Management has narrowed its fiscal 2026 revenue guidance to an organic decline of 1% to 2%, projecting limited impact from new product launches until late 2027. Investors buying Zoetis at current prices are effectively betting that the company can fix its sales issues while maintaining high profit margins. The stock appears to already price in a scenario where Zoetis owns a highly profitable but non-growing business. Key metrics to watch include fourth-quarter dermatology sales, which are expected to be reported in February 2027, as well as the success of new launches like long-acting Cytopoint.